Venture & Growth Strong veterinary AI driven oncology platform with expanding human healthcare ambitions and recent facility expansion in Palo Alto offers cross-selling opportunities to human oncology institutions seeking AI-driven precision medicine partnerships.

Medical Advances Recent launch of advanced PARR and flow cytometry services for feline lymphoma and exposure at ASH suggest a momentum in diagnostic capabilities that can be marketed to veterinary clinics and research centers needing cutting-edge diagnostic tools.

Financial Health Series A funding of 23 million and revenue in the low tens of millions indicate growth potential and capacity for partnerships, co-development deals, or pilot programs with larger biotech or veterinary firms.

Scale & Reach Deployment across more than 40 states and 22,000+ tests demonstrate a proven distribution and operations model ripe for expansions into new markets, regional sales partnerships, and channel financing with clinics and hospitals.

Strategic Alliances Participation in Mayo Clinic Platform Accelerate and exposure to hematology research at ASH create openings for collaboration agreements, data-sharing pilots, and joint development with academic medical centers and large veterinary networks.